Angiogenesis	0	12	O
associated	13	23	O
with	24	28	O
visceral	29	37	B-Tissue
and	38	41	O
subcutaneous	42	54	B-Tissue
adipose	55	62	I-Tissue
tissue	63	69	I-Tissue
in	70	72	O
severe	73	79	O
human	80	85	B-Organism
obesity	86	93	O
.	93	94	O

OBJECTIVE	96	105	O
:	105	106	O
The	107	110	O
expansion	111	120	O
of	121	123	O
adipose	124	131	B-Tissue
tissue	132	138	I-Tissue
is	139	141	O
linked	142	148	O
to	149	151	O
the	152	155	O
development	156	167	O
of	168	170	O
its	171	174	O
vasculature	175	186	B-Multi-tissue_structure
.	186	187	O

However	188	195	O
,	195	196	O
the	197	200	O
regulation	201	211	O
of	212	214	O
adipose	215	222	B-Tissue
tissue	223	229	I-Tissue
angiogenesis	230	242	O
in	243	245	O
humans	246	252	B-Organism
has	253	256	O
not	257	260	O
been	261	265	O
extensively	266	277	O
studied	278	285	O
.	285	286	O

Our	287	290	O
aim	291	294	O
was	295	298	O
to	299	301	O
compare	302	309	O
the	310	313	O
angiogenesis	314	326	O
associated	327	337	O
with	338	342	O
subcutaneous	343	355	B-Tissue
adipose	356	363	I-Tissue
tissue	364	370	I-Tissue
(	371	372	O
SAT	372	375	B-Tissue
)	375	376	O
and	377	380	O
visceral	381	389	B-Tissue
adipose	390	397	I-Tissue
tissue	398	404	I-Tissue
(	405	406	O
VAT	406	409	B-Tissue
)	409	410	O
from	411	415	O
the	416	419	O
same	420	424	O
obese	425	430	O
patients	431	439	B-Organism
in	440	442	O
an	443	445	O
in	446	448	O
vivo	449	453	O
model	454	459	O
.	459	460	O

RESEARCH	461	469	O
DESIGN	470	476	O
AND	477	480	O
METHODS	481	488	O
:	488	489	O
Adipose	490	497	B-Tissue
tissue	498	504	I-Tissue
samples	505	512	I-Tissue
from	513	517	O
visceral	518	526	O
(	527	528	O
VAT	528	531	B-Tissue
)	531	532	O
and	533	536	O
subcutaneous	537	549	O
(	550	551	O
SAT	551	554	B-Tissue
)	554	555	O
sites	556	561	O
,	561	562	O
obtained	563	571	O
from	572	576	O
36	577	579	O
obese	580	585	O
patients	586	594	B-Organism
(	595	596	O
mean	596	600	O
BMI	601	604	O
46	605	607	O
.	607	608	O
5	608	609	O
kg	610	612	O
/	612	613	O
m	613	614	O
(	614	615	O
2	615	616	O
)	616	617	O
)	617	618	O
during	619	625	O
bariatric	626	635	O
surgery	636	643	O
,	643	644	O
were	645	649	O
layered	650	657	O
on	658	660	O
chick	661	666	B-Organism
chorioallantoic	667	682	B-Multi-tissue_structure
membrane	683	691	I-Multi-tissue_structure
(	692	693	O
CAM	693	696	B-Multi-tissue_structure
)	696	697	O
.	697	698	O

RESULTS	699	706	O
:	706	707	O
Both	708	712	O
SAT	713	716	B-Tissue
and	717	720	O
VAT	721	724	B-Tissue
expressed	725	734	O
angiogenic	735	745	O
factors	746	753	O
without	754	761	O
significant	762	773	O
difference	774	784	O
for	785	788	O
vascular	789	797	B-Gene_or_gene_product
endothelial	798	809	I-Gene_or_gene_product
growth	810	816	I-Gene_or_gene_product
factor	817	823	I-Gene_or_gene_product
(	824	825	O
VEGF	825	829	B-Gene_or_gene_product
)	829	830	O
expression	831	841	O
.	841	842	O

Adipose	843	850	B-Tissue
tissue	851	857	I-Tissue
layered	858	865	O
on	866	868	O
CAM	869	872	B-Multi-tissue_structure
stimulated	873	883	O
angiogenesis	884	896	O
.	896	897	O

Angiogenic	898	908	O
stimulation	909	920	O
was	921	924	O
macroscopically	925	940	O
detectable	941	951	O
,	951	952	O
with	953	957	O
engulfment	958	968	O
of	969	971	O
the	972	975	O
samples	976	983	O
,	983	984	O
in	985	987	O
39	988	990	O
%	990	991	O
and	992	995	O
was	996	999	O
evidenced	1000	1009	O
by	1010	1012	O
angiography	1013	1024	O
in	1025	1027	O
59	1028	1030	O
%	1030	1031	O
of	1032	1034	O
the	1035	1038	O
samples	1039	1046	O
.	1046	1047	O

A	1048	1049	O
connection	1050	1060	O
between	1061	1068	O
CAM	1069	1072	B-Multi-tissue_structure
and	1073	1076	O
adipose	1077	1084	B-Tissue
tissue	1085	1091	I-Tissue
vessels	1092	1099	I-Tissue
was	1100	1103	O
evidenced	1104	1113	O
by	1114	1116	O
immunohistochemistry	1117	1137	O
,	1137	1138	O
with	1139	1143	O
recruitment	1144	1155	O
of	1156	1158	O
both	1159	1163	O
avian	1164	1169	B-Organism
and	1170	1173	O
human	1174	1179	B-Organism
endothelial	1180	1191	B-Cell
cells	1192	1197	I-Cell
.	1197	1198	O

The	1199	1202	O
angiogenic	1203	1213	O
potency	1214	1221	O
of	1222	1224	O
adipose	1225	1232	B-Tissue
tissue	1233	1239	I-Tissue
was	1240	1243	O
not	1244	1247	O
related	1248	1255	O
to	1256	1258	O
its	1259	1262	O
localization	1263	1275	O
(	1276	1277	O
with	1277	1281	O
an	1282	1284	O
angiogenic	1285	1295	O
stimulation	1296	1307	O
in	1308	1310	O
60	1311	1313	O
%	1313	1314	O
of	1315	1317	O
SAT	1318	1321	B-Tissue
samples	1322	1329	I-Tissue
and	1330	1333	O
61	1334	1336	O
%	1336	1337	O
of	1338	1340	O
VAT	1341	1344	B-Tissue
samples	1345	1352	I-Tissue
)	1352	1353	O
or	1354	1356	O
to	1357	1359	O
adipocyte	1360	1369	B-Cell
size	1370	1374	O
or	1375	1377	O
inflammatory	1378	1390	O
infiltrate	1391	1401	O
assessed	1402	1410	O
in	1411	1413	O
adipose	1414	1421	B-Tissue
samples	1422	1429	I-Tissue
before	1430	1436	O
the	1437	1440	O
graft	1441	1446	B-Tissue
on	1447	1449	O
CAM	1450	1453	B-Multi-tissue_structure
.	1453	1454	O

Stimulation	1455	1466	O
of	1467	1469	O
angiogenesis	1470	1482	O
by	1483	1485	O
adipose	1486	1493	B-Tissue
tissue	1494	1500	I-Tissue
was	1501	1504	O
nearly	1505	1511	O
abolished	1512	1521	O
by	1522	1524	O
bevacizumab	1525	1536	B-Drug_or_compound
,	1536	1537	O
which	1538	1543	O
specifically	1544	1556	O
targets	1557	1564	O
human	1565	1570	B-Organism
VEGF	1571	1575	B-Gene_or_gene_product
.	1575	1576	O

CONCLUSIONS	1577	1588	O
:	1588	1589	O
We	1590	1592	O
have	1593	1597	O
established	1598	1609	O
a	1610	1611	O
model	1612	1617	O
to	1618	1620	O
study	1621	1626	O
the	1627	1630	O
regulation	1631	1641	O
of	1642	1644	O
angiogenesis	1645	1657	O
by	1658	1660	O
human	1661	1666	B-Organism
adipose	1667	1674	B-Tissue
tissue	1675	1681	I-Tissue
.	1681	1682	O

This	1683	1687	O
model	1688	1693	O
highlighted	1694	1705	O
the	1706	1709	O
role	1710	1714	O
of	1715	1717	O
VEGF	1718	1722	B-Gene_or_gene_product
in	1723	1725	O
angiogenesis	1726	1738	O
in	1739	1741	O
both	1742	1746	O
SAT	1747	1750	B-Tissue
and	1751	1754	O
VAT	1755	1758	B-Tissue
.	1758	1759	O

